Latest On Ascendis Pharma A/S (ASND):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-08 18:47 EST | News | Ascendis Pharma added to Wedbush's best ideas list | N/A |  |
| 2023-05-02 17:38 EST | News | Ascendis Pharma Q1 Earnings: Skytrofa Soars, PTH Hurdles Yet To Clear | N/A | |
| 2023-05-01 17:06 EST | News | Ascendis' TransCon gets FDA rejection but company hopeful as no new trials requested | N/A | |
| 2023-04-28 02:05 EST | News | Ascendis Pharma A/S (ASND) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-04-27 01:02 EST | News | Ascendis Pharma Q1 2023 Earnings Preview | N/A | |
About Ascendis Pharma A/S (ASND):
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
General
- Name Ascendis Pharma A/S
- Symbol ASND
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 482
- Fiscal Year EndDecember
- IPO Date2015-01-28
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.ascendispharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 917.83
- Price/Book (Most Recent Quarter) 8.08
- Enterprise Value Revenue 1052.08
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$8.67
- Next Year EPS Estimate -$7.26
- Next Quarter EPS Estimate -$2.01
- Return on Assets -25%
- Return on Equity -58%
- Earnings Per Share -$5.09
- Revenue Per Share $0
- Gross Profit 6.95 million
- Quarterly Earnings Growth -78.7%
Highlights
- Market Capitalization 7.87 billion
- Analyst Target Price $194.63
- Book Value Per Share $8.43
Share Statistics
- Shares Outstanding 53.75 million
- Shares Float 43.76 million
- % Held by Insiders 3%
- % Held by Institutions 101.6%
- Shares Short 2.48 million
- Shares Short Prior Month 2.21 million
- Short Ratio 11.66
- Short % of Shares Outstanding 5%
Technicals
- Beta 0.79
- 52 Week High $183.98
- 52 Week Low $96.24
- 50 Day Moving Average 152.16
- 200 Day Moving Average 158.57
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Ascendis Pharma A/S (ASND) Dividend Calendar:
Ascendis Pharma A/S (ASND) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Ascendis Pharma A/S (ASND) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Ascendis Pharma A/S (ASND) Chart:
Ascendis Pharma A/S (ASND) News:
Below you will find a list of latest news for Ascendis Pharma A/S (ASND) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Ascendis Pharma A/S (ASND) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest ASND Trades:
Ascendis Pharma A/S (ASND) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-16 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-10-08 | SC 13G (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-10-05 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-29 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-23 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-10 | SC 13G/A (Statement of acquisition of beneficial ownership by individuals) | |
| 2020-09-10 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-09-08 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-27 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-08-13 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-17 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-15 | CT ORDER (Confidential treatment order) | |
| 2020-07-10 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-09 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-06 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-06 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-07-01 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |
| 2020-07-01 | 6-K (Report of foreign issuer [Rules 13a-16 and 15d-16]) | |